Optimizing the use of cyclosporine in renal transplantation

Clinical Biochemistry

Volumn 28, Issue 3, 1995, Pages 195-211

  Sketris, Ingrid ^a   Yatscoff, Randall ^b   Keown, Paul ^c   Canafax, Daniel M ^d   First, M Roy ^e   Holt, David W ^f   Schroeder, Timothy J ^e   Wright, Matthew ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

analysis; Cyclosporine; guidelines; immunosuppression; interactions; metabolites; microemulsion; monitoring; pharmacokinetics; renal; transplantation

Indexed keywords

CYCLOSPORIN; 15 DEOXYSPERGUALIN; CYCLOSPORIN A; LEFLUNOMIDE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

DRUG MONITORING; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; REVIEW; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; SIDE EFFECT;

CYCLOSPORINE; DRUG MONITORING; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION;

EID: 0028980088     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-9120(95)91341-Y     Document Type: Review

References (183)

1. Renal transplantation
2. A randomized clinical trial of Cyclosporine in cadaveric renal transplantation Analysis at three years
3. Renal allograft survival after 1 and 10 years: Comparison between Precyclosporine and Cyclosporin data
4. Adjustment of cyclosporine dosage in renal transplant patients based on concentration measured specifically in whole blood: clinical outcome results and diagnostic utility
5. Methodologic and clinical aspects of cyclosporin monitoring. Report of the Association of Clinical Biochemists Task Force
6. The use of immunosuppressive drugs in kidney transplantation
7. Long-term benefits and risks of cyclosporine therapy
8. Antilymphocyte globulins in kidney transplantation
9. The UNOS scientific renal transplant registry
10. Renal transplant function after ten years of Cyclosporine
11. Causes of late renal allograft failure in the cyclosporin era
12. Relationship between Cyclosporine bioavailability and clinical outcome in renal transplant recipients
13. Risk factors for chronic rejection in renal allograft recipients
14. An alternative view minimizing the significance of Cyclosporine nephrotoxicity and in favour of enhanced immunosuppression for long-term kidney transplant recipients
15. Renal allograft survival: Chronic rejection and the impact of immunosuppression
16. Prevention and management of the adverse effects associated with immunosuppressive therapy
17. A retrospective analysis of late renal graft function: Correlation with mean cyclosporine levels and lack of evidence for chronic Cyclosporine toxicity
18. Cancer in the immunosuppressed organ recipient
19. Mechanism of Cyclosporine-induced hypertension
20. New issues in therapy after renal transplantation
21. Long-term efficacy and safety of Cyclosporine in renal transplant recipients
22. Stability of renal allograft function associated with long-term Cyclosporine immunosuppressive therapy-five year follow-up. T
23. Stability of renal allograft function associated with long-term Cyclosporine immunosuppressive therapy-five year follow-up
24. Dosage forms of cyclosporine
25. Pharmacokinetics and tolerability of a microemulsion formulation of Cyclosporine in renal allograft recipients: A concentration-controlled comparison with the commercial formulation
26. Improvement of peroral absorption of Cyclosporine A by microemulsions
27. Bioequivalence: A Canadian regulatory perspective
28. Bioavailability testing of medicinal products and harmonization of international testing requirements and standards: The Canadian perspective
29. Intraindividual variability in the relative systemic availability of Cyclosporin after oral dosing
30. Absorption profiles of renal allograft recipients receiving oral doses of cyclosporine: A pharmacokinetic study
31. Cyclosporin clinical pharmacokinetics
32. Evidence for zero order absorption of Cyclosporine A
33. On the dose dependency of Cyclosporin A absorption and disposition in healthy volunteers
34. Metabolism of triglycerols
35. The absorption site of Cyclosporin in the human gastrointestinal tract
36. The pharmacokinetics of Cyclosporine A with special emphasis on bioavailability
37. Localization of Cyclosporin A absorption in rat small bowel and the effect of bile
38. Factors influencing the pharmacokinetics of Cyclosporine in man
39. Cyclosporin absorption from microemulsion formulation in liver transplant recipient [Letter]
40. Ursodeoxycholic acid enhances the absorption of Cyclosporine in a heart transplant patient with short bowel syndrome
41. Enhancement of the Oral Absorption of Cyclosporin in Man
42. Cyclosporine absorption in two patients with short-bowel syndrome
43. The effect of oral metoclopramide on the absorption of Cyclosporine
44. Oral administration of Cyclosporin A for recipients of allogenic marrow transplants: Implications of clinical gut dysfunction
45. Small-bowel length and the dose of Cyclosporine in children after liver transplantation
46. The effect of food on cyclosporine absorption
47. Effect of food on the pharmacokinetics of Cyclosporine in healthy subjects following oral and intravenous administration
48. Effects of dietary fat on the; pharmacokinetics and pharmacodynamics of Cyclosporin in renal transplant recipients
49. Bioavailability of Cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
50. Concentrations of Cyclosporine A and its metabolites in human tissues postmortem
51. Metabolism of Cyclosporine A. IV. Purification and identification of the rifampicin-inducible human liver Cytochrome P-450 (Cyclosporine A Oxidase) as a product of P450IIIA gene subfamily
52. Cyclosporin metabolism by human gastrointestinal mucosal microsomes
53. Cyclosporin metabolism by the gastrointestinal mucosa
54. Cyclosporin A metabolism in human liver, kidney and intestine slices. Comparison to rat and dog slices and human cell lines
55. First-pass metabolism of Cyclosporine by the gut
56. The effect of Ketoconazole on the intestinal metabolism and bioavailability of Cyclosporine
57. Clinical pharmacokinetics of Cyclosporine
58. The Cyclosporine-Erythromycin interaction: Impaired first pass metabolism in the pig
59. Cyclosporine kinetics in liver disease
60. Cyclosporine A: Pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogenic bone-marrow grafts
61. Effect of bile on Cyclosporin absorption in liver transplant patients
62. The effect of food and bile acid administration on the relative bioavailability of Cyclosporine
63. Pharmacokinetics of Cyclosporine A after intravenous and oral administration in liver transplant patients measured with high-performance liquid chromatography
64. On the intra-individual variability and chronobiology of Cyclosporine pharmacokinetics in renal transplantation
65. High-fat meals increase the clearance of Cyclosporine
66. Effect of grapefruit juice on blood concentrations of Cyclosporine
67. Demographic factors affecting the pharmacokinetics of Cyclosporine estimated by radioimmunoassay
68. Influence of Cyclosporine pharmacokinetics, trough concentrations and AUC monitoring on outcome after kidney transplantation
69. Long-term Cyclosporine pharmacokinetic changes in renal transplant recipients: Effects of binding and metabolism
70. Cyclosporine pharmacokinetic profiles in liver, heart and kidney transplant patients as determined by high-performance liquid chromatography
71. Detrimental effect of intestinal disease on absorption of orally administered Cyclosporine
72. Demographic factors influencing Cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
73. Comparative analyses of Cyclosporine in whole blood and plasma by radioimmunoassay, fluorescence polarization immunoassay and high-performance liquid chromatography
74. Effects of Cyclosporine therapy on plasma lipoprotein levels
75. Distribution of Cyclosporine in blood of a renal-transplant recipient with Type V Hyperlipoproteinemia
76. Distribution of the Cyclosporine binding protein Cyclophilin in human tissues
77. Cyclosporine metabolism in human liver: Identification of a Cytochrome P-450III gene family as the major Cyclosporine-metabolizing enzyme explains interactions of Cyclosporine with other drugs
78. Age-dependent Cyclosporine: Pharmacokinetics in marrow transplant recipients
79. Extraction ratio of Cyclosporine in a liver transplant patient with organ rejection
80. Management of drug interactions with Cyclosporine
81. The chronopharmacokinetics of Cyclosporine and its metabolites in recipients of pancreas allografts
82. Diurnal variations of Cyclosporine and metabolites in renal transplant patients
83. The effect of food and cholestyramine on the absorption of Cyclosporine in cardiac transplant recipients
84. Pharmacokinetic drug interactions with Cyclosporine (Part I)
85. Pharmacokinetic drug interactions with Cyclosporine (Part II)
86. Cyclosporin and calcium channel blockers: An exploitable drug interaction?
87. Interaction between Cyclosporine and diltiazem in renal transplant patients [Letter]
88. Improved outcome of cadaveric renal transplantation due to channel blockers
89. Calcium channel blockers and early Cyclosporine nephrotoxicity after renal transplantation. A prospective randomized study
90. Renal transplantation: Nifedipine for the nonstarters? A prospective randomised study
91. Effect of calcium channel blockers on Cyclosporine clearance and use in renal transplant patients
92. The impact of calcium channel blockers on Cyclosporine A levels and therapeutic effects
93. A preliminary study of Diltiazem in the prevention of coronary artery disease in heart-transplant recipients
94. Immunosuppressive properties of calcium channel blockers
95. The Cyclosporine sparing effects of diltiazem in renal transplantation
96. Biologic activity of Cyclosporine metabolites
97. Influence of concomitant medication on Cyclosporine dosage and blood concentrations in renal allograft recipients
98. Cyclosporine and Ketoconazole, Drug interaction or therapeutic association?
99. Prospective study of the safety and financial benefit of Ketoconazole as adjunctive therapy to Cyclosporine after heart transplantation
100. Concomitant administration of Cyclosporine and Ketoconazole in renal transplant recipients
101. Cyclosporine dose reduction by Ketoconazole administration in renal transplant patients
102. The Ketoconazole-Cyclosporine interaction in an elderly renal transplant patient
103. Cyclosporine-Ketoconazole interaction
104. Canadian consensus meeting on Cyclosporine monitoring: Report of the consensus panel
105. Critical issues in Cyclosporine monitoring: Report on the task force on Cyclosporine monitoring
106. Consensus document, Hawk's Cay meeting on therapeutic monitoring of cyclosporine
107. Quality assurance programs for immunosuppressive drugs: Cyclosporine and beyond
108. Pharmacology of Cyclosporine (Sandimmune) III Immunochemistry and monitoring
109. A comparison of the clinical utility of the radioimmunoassay, highperformance liquid chromatography and TDX Cyclosporine assays in outpatient renal transplant recipients
110. The clinical significance of Cyclosporine, metabolites
111. Cyclosporine metabolism in transplant patients
112. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation
113. Abbott TDx monoclonal antibody assay evaluated for measuring Cyclosporine in whole blood
114. Comparison of cyclosporine measurement in whole blood by high-performance liquid chromatography, monoclonal fluorescence polarization immunoassay and monoclonal enzyme-multiplied immunoassay
115. Is the monoclonal fluorescence polarization immunoassay for Cyclosporine specific? Comparison with specific radioimmunoassay
116. Evaluation of EMIT® Cyclosporine assay for use with whole blood
117. A comparison of Cyclosporine assays using sequential samples from selected transplant patients
118. Considerations for monitoring Cyclosporine in transplant recipients
119. Measurement of Cyclosporine in plasma of cardiac allograft recipients by fluorescence polarization immunoassay
120. Optimization of Cyclosporine therapy in renal transplantation by a pharmacokinetic strategy
121. Cyclosporine monitoring in renal transplantation: Area under the curve monitoring is superior to trough-level monitoring
122. Cyclosporine plasma levels six hours after oral administration. A useful tool for monitoring therapy
123. A limited sampling strategy for the measurement of Cyclosporine AUC
124. The adverse impact of high Cyclosporine clearance rates on the incidences of acute rejection and graft loss
125. Efficacy of area under the curve Cyclosporine monitoring in renal transplantation
126. Utility of pretransplantation Cyclosporine pharmacokinetic studies
127. Therapeutic drug monitoring and patient outcome. A review of the issues
128. What is the dose-response curve for the effects of Cyclosporine on calcineurin and cytokine induction in vivo?
129. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity
130. Calcineurin phosphate activity in T-lymphocytes is inhibited by FK506 and Cyclosporine A
131. Calcineurin is a common target of Cyclophillin-Cyclosporine A and FKBP-FK506 complexes
132. Nephrotoxic and immunosuppressive potentials of Cyclosporine metabolites in rats
133. Biologic significance of Cyclosporine metabolites
134. Pharmacology of Cyclosporine (Sandimmune) VII Pathophysiology and toxicology of Cyclosporine in humans and animals
135. Comparison of the effects of Cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells
136. Ciclosporin metabolite pattern in blood and urine of liver graft recipients, II. Influence of cholestasis and rejection
137. Therapeutic monitoring for Cyclosporine: Difficulties in establishing a therapeutic window
138. Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood
139. Predictors of severe renal dysfunction after heart transplantation and intravenous Cyclosporine therapy
140. Diagnostic utility of whole blood Cyclosporine measurements in renal transplantation using triple therapy
141. Rapamycin Antifungal antitumor antiproliferative and immunosuppressive macrolides
142. RS-61443 — A new, potent immunosuppressive agent
143. RS-61443-A phase I clinical trial and pilot rescue study
144. Therapeutic monitoring of rapamycin: A new immunosuppressive drug
145. Liver, kidney and thoracic organ transplantation under FK 506
146. Randomized trial comparing tacrolimus (FK506) and Cyclosporin in the prevention of liver allograft rejection
147. Leflunomide, A novel immunosuppressive agent
148. A comparison of tacrolimus (FK506) and Cyclosporine for immunosuppression in liver transplantation
149. Differential diagnosis of renal allograft biopsies
150. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
151. Protocol biopsies in stable renal transplant patients under triple immunosuppression: Results at 6 months
152. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation
153. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of Cyclosporine concentrations in renal allograft recipients
154. Consensus statements on the optimal use of Cyclosporine in pediatric patients
155. Weight-independent dosing of Cyclosporine — An alterntive to the “mg/kg” doctrine
156. Role of patient compliance in clinical pharmacokinetics. A review of recent research
157. Causes of graft loss beyond two years in the Cyclosporine era
158. Patient noncompliance: A major cause of late graft failure in cyclosporine-treated renal transplants
159. Noncompliance in organ transplant recipients
160. Factors affecting compliance with Cyclosporine in adult renal transplant patients
161. The socioeconomics of organ transplantation
162. The pharmacoeconomics of renal transplantation: Increased drug costs with decreased hospitalization costs
163. The effect of cyclosporine on the use of hospital resources for kidney transplantation
164. Improved dose linearity of Cyclosporine pharmacokinetics from a microemulsion formulation
165. Safety and steady-state pharmacokinetics of a new oral formulation of Cyclosporine A in renal transplant patients
166. The pharmacokinetics of Sandimmune Neoral®: A new oral formulation of Cyclosporine
167. Comparison of the pharmacokinetics of SIM® with Sandimmune Neoral® in stable renal transplant patients
168. Increased Cyclosporine bioavailability from a microemulsion formulation in a liver transplant recipient [Letter]
169. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of Cyclosporine in a crossover comparison with the market formulation
170. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation
171. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmune Neoral® in renal transplant patients
172. Neurol: A new formulation of ciclosporin
173. Enhanced absorption of new oral cyclosporin microemulsion formulation neoral in liver transplant recipients with external biliary diversion
174. Cyclosporine Neoral in liver transplantation
175. The Neoral® Formulation: Improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients